AbbVie Inc. (NYSE:ABBV) is included among the 15 Best DRIP Stocks to Own Right Now. On November 5, Piper San‍dler​ analyst ...

AbbVie's Q3 2025 earnings are in. Skyrizi is on fire, neuroscience is booming, but Botox is a bust. Get the summary.

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Patients with refractory Crohn’s disease who previously received ustekinumab experienced clinical and endoscopic improvements ...

For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

The pharma company's newer immunology drugs, Skyrizi and Rinvoq, have delivered robust sales growth that's proving to be the ...

Skyrizi and Rinvoq sold nearly seven billion dollars, almost half of the company’s income for the quarter alone.

Skyrizi (risankizumab-rzaa) is a prescription injection that’s used to treat certain autoimmune disorders, such as plaque psoriasis and Crohn’s disease. Skyrizi comes in a few different forms for ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

People with Crohn’s disease often take medicines to help manage their condition and improve their symptoms. Some of these medicines are taken by mouth and stay inside of the digestive tract. But ...

People with psoriatic arthritis (PsA) often take medicines to help manage their condition and improve their symptoms. Some of these medicines work directly on the body’s immune system and help to ...

Skyrizi is a prescription drug used to treat certain autoimmune conditions, such as Crohn’s disease, in adults. There are currently no known interactions between Skyrizi and other medications, alcohol ...